of /kg Infliximab

Phase 2Monoclonal antibody

UUniversity of Liverpool

of /kg Infliximab is one of 38 small molecule programs targeting Acute Pancreatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute PancreatitisActive, not recruiting

Acute PancreatitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

69 competitors in Acute Pancreatitis

#DrugCompanyPhaseTrials

Primaxin

Pfizer

Approved

1 2

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Approved

1 3

VIOKACE

DDigestive Care, Inc.

Approved

1 4

Relistor

Zocor

Octreotide

1 7

Balanced Crystalloid

SSeoul National University Hospital

Approved

1 8

Indocin

LLife Extension Foundation Inc.

Phase 3

3 9

Trental

VValidus Pharmaceuticals

Phase 3

2 10

Ursodeoxycholic Acid

Daewoong Pharmaceutical Co. LTD.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Acute Pancreatitis

NCT03684278

Clinical

Trials by Indication[1]

Acute Pancreatitis1 trial

Phase IIb, Randomised, Double-blind, Placebo-controlled, Multi-centre Trial of Infliximab With Transcriptomic Biomarker and Mechanism Evaluation in Patients With Acute Pancreatitis.

Recruiting·UUniversity of Liverpool·Phase 2·NCT03684278·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for of /kg Infliximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — of /kg Infliximab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for of /kg Infliximab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Liverpool company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Liverpool

of /kg Infliximab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Acute Pancreatitis1 trial

References

Drug Info

Quick Facts

Related News